Which blood-based technologies did the speaker identify as most promising for routine practice in multiple myeloma?
Circulating tumor cells (CTCs) at diagnosis, which may explain unexpected early relapse in genomically standard-risk patients, and mass spectrometry, which could help decide when a bone marrow test is needed
Cell-free DNA as a replacement for all bone marrow sampling, and absolute lymphocyte count as the primary measure of response
Serum protein electrophoresis and free light chain assays, which have replaced the need for MRD testing